MRNA · News · 20260807N
Guidance / Outlook
Moderna, Inc. · 2026-08-07 · Importance 59 · Surprise 32 · No source text
On its second-quarter 2026 earnings call, Moderna reiterated a target of up to 10% revenue growth for full-year 2026. Management also tightened its cost-of-sales and research-and-development guidance while emphasizing cost reductions and continued advancement of late-stage pipeline programs. The outlook is intended to support revenue growth as Moderna commercializes its newly approved influenza vaccine and reduces reliance on COVID-19 products. The reported 2026 guidance represents management’s forward view rather than a historical performance metric.
Key facts
- Moderna reiterated its target of up to 10% revenue growth for 2026. source
- Moderna said it tightened cost-of-sales and R&D guidance on the Q2 2026 earnings call. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Moderna reiterated its target of up to 10% revenue growth for 2026. |